دورية أكاديمية
Disease-Associated Risk Variants in ANRIL Are Associated with Tumor-Infiltrating Lymphocyte Presence in Primary Melanomas in the Population-Based GEM Study.
| العنوان: | Disease-Associated Risk Variants in ANRIL Are Associated with Tumor-Infiltrating Lymphocyte Presence in Primary Melanomas in the Population-Based GEM Study. |
|---|---|
| المؤلفون: | Davari DR; Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Orlow I; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Kanetsky PA; Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, Florida., Luo L; Department of Internal Medicine, University of New Mexico Cancer Center, University of New Mexico, Albuquerque, New Mexico., Edmiston SN; Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Conway K; Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Parrish EA; Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Hao H; Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Busam KJ; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Sharma A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Kricker A; Sydney School of Public Health, The University of Sydney, Sydney, Australia., Cust AE; Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia.; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Anton-Culver H; Department of Epidemiology, University of California, Irvine, Irvine, California., Gruber SB; City of Hope National Medical Center, Duarte, California., Gallagher RP; BC Cancer and Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada., Zanetti R; Piedmont Cancer Registry, Centre for Epidemiology and Prevention in Oncology in Piedmont, Turin, Italy., Rosso S; Piedmont Cancer Registry, Centre for Epidemiology and Prevention in Oncology in Piedmont, Turin, Italy., Sacchetto L; Piedmont Cancer Registry, Centre for Epidemiology and Prevention in Oncology in Piedmont, Turin, Italy., Dwyer T; Murdoch Children's Research Institute, Melbourne, Australia.; The Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom.; Department of Pediatrics, University of Melbourne, Melbourne, Australia.; Oxford Martin School, University of Oxford, Oxford, United Kingdom., Ollila DW; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Begg CB; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Berwick M; Department of Internal Medicine, University of New Mexico Cancer Center, University of New Mexico, Albuquerque, New Mexico., Thomas NE |
| مؤلفون مشاركون: | GEM Study Group |
| المصدر: | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2021 Dec; Vol. 30 (12), pp. 2309-2316. Date of Electronic Publication: 2021 Oct 04. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9200608 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7755 (Electronic) Linking ISSN: 10559965 NLM ISO Abbreviation: Cancer Epidemiol Biomarkers Prev Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, PA : American Association for Cancer Research, c1991- |
| مواضيع طبية MeSH: | Cyclin-Dependent Kinase Inhibitor p15*, Lymphocytes, Tumor-Infiltrating/*pathology , Melanoma/*genetics , Skin Neoplasms/*genetics, Aged ; Female ; GTP Phosphohydrolases ; Genome-Wide Association Study ; Humans ; Male ; Melanoma/pathology ; Membrane Proteins ; Middle Aged ; Mutation ; Proto-Oncogene Proteins B-raf ; Skin Neoplasms/pathology ; Melanoma, Cutaneous Malignant |
| مستخلص: | Background: Genome-wide association studies have reported that genetic variation at ANRIL ( CDKN2B-AS1 ) is associated with risk of several chronic diseases including coronary artery disease, coronary artery calcification, myocardial infarction, and type 2 diabetes mellitus. ANRIL is located at the CDKN2A/B locus, which encodes multiple melanoma tumor suppressors. We investigated the association of these variants with melanoma prognostic characteristics. Methods: The Genes, Environment, and Melanoma Study enrolled 3,285 European origin participants with incident invasive primary melanoma. For each of ten disease-associated SNPs at or near ANRIL , we used linear and logistic regression modeling to estimate, respectively, the per allele mean changes in log of Breslow thickness and ORs for presence of ulceration and tumor-infiltrating lymphocytes (TIL). We also assessed effect modification by tumor NRAS/BRAF mutational status. Results: Rs518394, rs10965215, and rs564398 passed false discovery and were each associated ( P ≤ 0.005) with TILs, although only rs564398 was independently associated ( P = 0.0005) with TILs. Stratified by NRAS/BRAF mutational status, rs564398*A was significantly positively associated with TILs among NRAS/BRAF mutant, but not wild-type, cases. We did not find SNP associations with Breslow thickness or ulceration. Conclusions: ANRIL rs564398 was associated with TIL presence in primary melanomas, and this association may be limited to NRAS/BRAF -mutant cases. Impact: Pathways related to ANRIL variants warrant exploration in relationship to TILs in melanoma, especially given the impact of TILs on immunotherapy and survival. (©2021 The Authors; Published by the American Association for Cancer Research.) |
| References: | J Invest Dermatol. 2007 May;127(5):1234-43. (PMID: 17218939) Bioinformatics. 2005 Mar;21(6):781-7. (PMID: 15454414) Atherosclerosis. 2012 Feb;220(2):449-55. (PMID: 22178423) N Engl J Med. 2007 Aug 2;357(5):443-53. (PMID: 17634449) Cancer. 1973 Dec;32(6):1446-57. (PMID: 4757934) Data Brief. 2016 Feb 15;7:229-42. (PMID: 26958643) Am J Clin Pathol. 2002 Oct;118(4):504-11. (PMID: 12375635) Eur J Surg Oncol. 2017 Mar;43(3):604-611. (PMID: 27769635) J Natl Cancer Inst. 2016 Feb 08;108(7):. (PMID: 26857527) Trends Endocrinol Metab. 2015 Apr;26(4):176-84. (PMID: 25744911) Mol Cell. 2010 Jun 11;38(5):662-74. (PMID: 20541999) J Clin Oncol. 2015 Sep 1;33(25):2780-8. (PMID: 26014293) J Natl Cancer Inst. 1989 Dec 20;81(24):1893-904. (PMID: 2593166) JAMA Oncol. 2015 Jun;1(3):359-68. (PMID: 26146664) Pathology. 2016 Feb;48(2):177-87. (PMID: 27020390) Int J Mol Sci. 2013 Jan 10;14(1):1278-92. (PMID: 23306151) Cancer. 1985 Jul 15;56(2):413-8. (PMID: 4005806) J Clin Oncol. 2013 Nov 20;31(33):4252-9. (PMID: 24127443) Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1671-7. (PMID: 19592466) Front Endocrinol (Lausanne). 2018 Jul 24;9:405. (PMID: 30087655) Int J Cancer. 2012 Jan 15;130(2):405-18. (PMID: 21365644) Mech Ageing Dev. 2007 May-Jun;128(5-6):370-7. (PMID: 17459456) J Cutan Pathol. 2011 May;38(5):394-400. (PMID: 21385199) Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):992-7. (PMID: 25837821) Int J Biol Sci. 2020 Feb 21;16(8):1463-1473. (PMID: 32210733) Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2932-41. (PMID: 20802019) Sci Rep. 2021 Jan 19;11(1):1834. (PMID: 33469107) Carcinogenesis. 2006 Mar;27(3):610-8. (PMID: 16258177) N Engl J Med. 2019 Oct 17;381(16):1535-1546. (PMID: 31562797) Science. 2007 Jun 8;316(5830):1491-3. (PMID: 17478679) Lancet Oncol. 2017 Apr;18(4):435-445. (PMID: 28284557) Cancer Immunol Immunother. 2020 Apr;69(4):653-662. (PMID: 32025849) Oncogene. 2011 Apr 21;30(16):1956-62. (PMID: 21151178) JAMA Dermatol. 2014 Dec;150(12):1306-314. (PMID: 25162299) Nat Med. 2018 Nov;24(11):1649-1654. (PMID: 30297909) Dermatol Ther. 2005 Sep-Oct;18(5):369-85. (PMID: 16297012) Lancet Oncol. 2018 May;19(5):603-615. (PMID: 29573941) Stat Med. 2020 Jan 30;39(2):103-113. (PMID: 31660633) J Clin Oncol. 2012 Jul 20;30(21):2678-83. (PMID: 22711850) Genet Epidemiol. 2013 Dec;37(8):759-67. (PMID: 24227293) Ann Surg Oncol. 2012 Mar;19(3):1024-33. (PMID: 21913010) Cancer Causes Control. 2004 Nov;15(9):957-65. (PMID: 15577298) Cancer Res. 1969 Mar;29(3):705-27. (PMID: 5773814) Int J Epidemiol. 2006 Jun;35(3):756-64. (PMID: 16556646) Nature. 2011 Feb 10;470(7333):264-8. (PMID: 21307941) Clin Cancer Res. 2019 Apr 15;25(8):2442-2449. (PMID: 30617133) PLoS Genet. 2010 Apr 08;6(4):e1000899. (PMID: 20386740) PLoS One. 2017 Mar 21;12(3):e0174234. (PMID: 28323902) RNA Biol. 2016;13(1):98-108. (PMID: 26618242) J Mol Diagn. 2001 Nov;3(4):158-63. (PMID: 11687599) Cancer. 1996 Apr 1;77(7):1303-10. (PMID: 8608507) Science. 2007 Jun 1;316(5829):1336-41. (PMID: 17463249) |
| معلومات مُعتمدة: | R01 CA197350 United States CA NCI NIH HHS; U01 CA083180 United States CA NCI NIH HHS; R01 CA233524 United States CA NCI NIH HHS; R03 CA103089 United States CA NCI NIH HHS; P30 CA016086 United States CA NCI NIH HHS; P30 CA008748 United States CA NCI NIH HHS; P01 CA206980 United States CA NCI NIH HHS; R01 CA098438 United States CA NCI NIH HHS; R01 CA112243 United States CA NCI NIH HHS; R03 CA173806 United States CA NCI NIH HHS; R01 CA112524 United States CA NCI NIH HHS; R03 CA125829 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (CDKN2B protein, human) 0 (Cyclin-Dependent Kinase Inhibitor p15) 0 (Membrane Proteins) EC 2.7.11.1 (BRAF protein, human) EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) EC 3.6.1.- (GTP Phosphohydrolases) EC 3.6.1.- (NRAS protein, human) |
| تواريخ الأحداث: | Date Created: 20211005 Date Completed: 20220304 Latest Revision: 20231213 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8643342 |
| DOI: | 10.1158/1055-9965.EPI-21-0686 |
| PMID: | 34607836 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1538-7755 |
|---|---|
| DOI: | 10.1158/1055-9965.EPI-21-0686 |